Cel-Sci Says Phase III Clinical Trial Moving Forward

CEL-SCI Corporation

announced today financial results for the fiscal quarter ended March 31, 2012. CEL-SCI reported that net loss available to common shareholders for the quarter ended March 31, 2012 was $(10,086,959) versus $(15,097,973) during the same quarter ended March 31, 2011. Net loss per common share, (basic) was $(0.04) for the quarter ended March 31, 2012 versus $(0.07) during the same quarter ended March 31, 2011. The operating loss for the quarter ended March 31, 2012 was $(4,262,357) versus $(5,096,996) during the same quarter ended March 31, 2011. Net loss available to common shareholders for the six months ended March 31, 2012 was $(14,243,792) versus $(21,348,925) million during the same six months ended March 31, 2011. Net loss per common share, (basic) was $(0.06) for the six months ended March 31, 2012 versus $($0.10) during the same six months ended March 31, 2011. The operating loss for the six months ended March 31, 2012 was $(8,705,633) versus $(9,413,030) during the same six months ended March 31, 2011.